Rating Change
Wells Fargo reiterated its Overweight rating on Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) on November 06, 2026.
reiterateNASDAQ:GLUE
Wells Fargo Reiterates Overweight Rating on Monte Rosa Therapeutics, Inc. (GLUE)
Wells Fargo reiterated its Overweight rating on Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) on November 06, 2026.
At publication ·
What changed
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) · reiterate
- Firm
- Wells Fargo
- Rating
- Overweight to Overweight
- Price at event
- $10.52
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Wells Fargo maintained its Overweight rating on Monte Rosa Therapeutics (GLUE) on November 6, 2026, as the stock trades at $10.52 with a $1.1B market cap.
Market Context
Monte Rosa Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $10.52 with a market capitalization of $1.1B. The stock has declined 23.0% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Monte Rosa Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Monte Rosa Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 06, 2026 | Wells Fargo | Overweight | N/A |
| Oct 05, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 09, 2026 | Wedbush | Outperform | N/A |
| Aug 25, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View GLUE Stock Page
Frequently Asked Questions
What does the Overweight rating mean for GLUE?
A rating of Overweight from Wells Fargo reflects the analyst's outlook on Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GLUE forecast page.